Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
19.42
+0.10 (0.52%)
At close: Nov 13, 2026, 4:00 PM EST
19.47
+0.05 (0.26%)
After-hours: Nov 13, 2026, 7:30 PM EST
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or 52.20% compared to the previous year. That makes Vor Biopharma the 33,105th largest employer in the world and 4,307th in the United States.
Employees
76
Change (1Y)
-83
Growth (1Y)
-52.20%
Revenue / Employee
n/a
Profits / Employee
$17,812,355
Market Cap
1.19B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | -83 | -52.20% |
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UroGen Pharma | 300 |
| Kardigan | 241 |
| Omeros | 175 |
| Alpha Tau Medical | 121 |
| Inhibrx Biosciences | 110 |
| Silence Therapeutics | 88 |
| SpyGlass Pharma | 88 |
| Savara | 70 |
VOR News
- 3 days ago - Vor Bio expands RemeGen license, adds RC298 for about $56M upfront - TheFly
- 3 days ago - Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise - GlobeNewsWire
- 5 days ago - Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 11 days ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - Vor Biopharma Quarterly report: Q3 2026 - Filings
- 16 days ago - Vor Biopharma Earnings release: Q3 2026 - Filings
- 24 days ago - Vor Bio says its experimental drug slowed loss of kidney function in late-stage study - Reuters